Health

New drug combo shrinks tumors in most patients facing aggressive cancer type

In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between 8 and 11 months.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 21, 2026, 1:07 AM UTC
Key points
  • FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS' SURVIVAL RATES NEARLY DOUBLE Patients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found.
  • In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans.
  • The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.

Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference.

Additional details
  • According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis.
  • Without a direct comparison group of patients receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival.
  • The findings also apply strictly to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers.
  • CLICK HERE FOR MORE HEALTH STORIES Side effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care.
  • Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said in a press release.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet